Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

Topline data from the phase IIb BiRCh trial in chronic rhinosinusitis ... Aficamten’s second planned indication, nonobstructive HCM (nHCM), represents a sizable market with no current approved drugs.

Better-than-expected Alzheimer's disease treatment sales and a quarterly beat not enough to offset below-consensus EPS outlook Biogen Inc.'s stock (BIIB) fell 0.6% early Wednesday, after the biotech ...

The average price of bud has fallen gradually, numbers show. Recreational sales grew 2.5% last year, with dispensaries ...

Zepbound's market share stands at just over 50%, according to IQVIA data shared by ... $1.9 billion in Zepbound sales this quarter. Analysts on average now expect the drug to bring in about ...

Sales of Eli Lilly’s (LLY ... call on Thursday when asked if the company is overestimating the weight-loss drug market. “We all we seek to put projections out that we can hit with confidence ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

It was the second time in a year its sales ... Zepbound's market share stands at just over 50%, according to IQVIA data shared by an analyst, with Lilly having started advertising the drug in ...